Latest Posters
Poster
Quantitative Cell-based Bioassays for Individual or Combination Immune Checkpoint Immunotherapy
Cell-based reporter bioassays overcome the limitations of primary cell-based assays for functional characterization of antibody and other biologics drugs, targeting individual or combination immune checkpoint receptors. Here we show a portfolio of immune inhibitory checkpoint bioassays, that can be used for antibody screening, characterization, potency and stability studies.
Poster
Fc Effector Bioassays for Rapid and Quantitative Measurement of ADCC and ADCP Mechanisms of Action
Drug developers are rapidly adopting Fc effector function reporter-based bioassays to measure antibody Fc functions such as ADCC and ADCP activity during the development of therapeutic antibodies. Here we show application of a suite of FcgR Reporter Bioassays to elucidate and characterize antibody MOA.
Poster
Bioluminescent Kinase Profiling Systems for Characterizing Small Molecule Kinase Inhibitors
In order to profile compounds against a broad panel of kinases, in-house profiling requires rigorous kinase assay development.
Poster
Pyroptosis Detection via Multiplexing Cell Death and Bioluminescent Caspase-1 Activity Assessments
Researchers developed a convenient method to confirm pyroptosis. Inflammasome activation triggers rapid pyroptosis. Preventing pyroptosis may shift form of cell death
Poster
Quantitative Cell-based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets
The human immune system is comprised of a complex network of immune checkpoint receptors that are promising new immunotherapy targets for the treatment of a variety of diseases including cancer and autoimmune-mediated disorders.
Poster
Automating Mass Spectrometry-Based Quantitative Glycomics using Tandem Mass Tag (TMT) Reagents with SimGlycan
One of the emerging trends in glycomics research is the innovation related to accurate MS based quantitative analysis of glycans.
Poster
Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
Inecalcitol is a vitamin D receptor agonist currently in Phase II clinical trial in AML (acute myeloid leukemia). Inecalcitol increases the expression of CD38 at the surface of 5 multiple myeloma cell lines; therefore, inecalcitol could potentiate the clinical response of MM patients to a therapeutic anti-CD38 antibody
Inecalcitol induces the expression of the CD38 antigen at the surface of 4 AML cell lines; thus, inecalcitol could render AML patients sensitive to a therapeutic anti-CD38.
Inecalcitol induces the expression of the CD38 antigen at the surface of 4 AML cell lines; thus, inecalcitol could render AML patients sensitive to a therapeutic anti-CD38.
Poster
Optimized Workflow for Single Cell Copy Number Profiling Using High Resolution Oligo CGH Arrays
Here we describe GenetiSure Pre-Screen, a same day, cost-effective, analysis workflow that combines whole genome amplification (WGA) with copy number (CN) profiling using high-resolution oligo CGH microarrays.
Poster
Touching BACE. How Inhibiting β-Amyloid Production by Steric Hindrance with a Novel Immunotherapy Improves Memory in PDAPP Mice
The work presented in this poster aims to assess whether intracerebroventricular (ICV) administration of 2B3 alleviated age dependent memory deficits in PDAPP mice and to determine whether 2B3 altered APP metabolism and NMDA receptor phosphorylation ex vivo.
Poster
Multiplexed Cell- and Bead-based Assays in a No-wash Format for Biologics Screening and Characterization
Here we present the results generated from multiplexed no-wash protocols using TTP Labtech’s mirrorball, a laser scanning cytometer.
Advertisement
